Ainos'药物VELDONA 获得绿灯 Sjogren综合症在台湾的试验。 Ainos' drug VELDONA gets green light for Sjogren's Syndrome trial in Taiwan.

Ainos是一家生命科学公司,已获得移民和难民局批准,在台北的Shuang Ho医院对Sjogren综合症进行临床试验。 Ainos, a life sciences firm, has received IRB approval for a clinical trial on Sjogren's Syndrome at Shuang Ho Hospital in Taipei. 试验将评估阿伊诺斯药物VELDONA的安全和功效。 在以前的研究中,该药物在流出口液方面有显著改善。 The trial will assess the safety and efficacy of Ainos' drug, VELDONA, which has shown significant improvement in salivary flow in previous studies. 这项研究定于2025年问题1开始,先进行现场启动访问并获得监管批准,目的是招募24名病人,治疗时间为24至48周。 The study, set to begin in Q1 2025 after a site initiation visit and regulatory approvals, aims to recruit 24 patients for a 24- to 48-week treatment period.